Evidence map›Paper›PMID 30680638›Full record

ArticleNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2019

Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes.

H G van Velzen, A F L Schinkel, R W J van Grootel, M A van Slegtenhorst, J van der Velden, M Strachinaru, M Michels

Abstract read
In one paragraph

Article in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants-design and status.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2021
    Article
  6. Seeing the disease before it has manifested itself.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H G van VelzenDepartment of Cardiology, Thorax Centre, Erasmus Medical Centre, Rotterdam, The Netherlands. h.g.vanvelzen@erasmusmc.nl.
A F L SchinkelDepartment of Cardiology, Thorax Centre, Erasmus Medical Centre, Rotterdam, The Netherlands.
R W J van GrootelDepartment of Cardiology, Thorax Centre, Erasmus Medical Centre, Rotterdam, The Netherlands.
M A van SlegtenhorstDepartment of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands.
J van der VeldenDepartment of Physiology, Amsterdam Cardiovascular Sciences, VU University Medical Centre, Amsterdam, The Netherlands.
M StrachinaruDepartment of Cardiology, Thorax Centre, Erasmus Medical Centre, Rotterdam, The Netherlands.
M MichelsDepartment of Cardiology, Thorax Centre, Erasmus Medical Centre, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to determine its prognostic value for the development of HCM. METHODS AND

resultsThis retrospective case-control and cohort study included 120 HCM mutation carriers and 110 controls. GLS and LVEF were assessed with Tomtec Imaging software. Age, gender, and body surface area were similar in mutation carriers and controls. Compared to controls, mutation carriers had a higher maximal wall thickness (9 ± 2 vs 8 ± 2 mm, p < 0.001), higher LVEF (60 ± 5 vs 58 ± 4%, p < 0.001) and higher GLS (-21.4 ± 2.3% vs -20.3 ± 2.2%, p < 0.001). The GLS difference was observed in the mid-left ventricle (-21.5 ± 2.5% vs -19.9 ± 2.5%, p < 0.001) and the apex (-24.1 ± 3.5% vs -22.1 ± 3.4%, p < 0.001), but not in the base of the left ventricle (-20.0 ± 3.3% vs -20.0 ± 2.6%, p = 0.9). Echocardiographic follow-up was performed in 80 mutation carriers. During 5.6 ± 2.9 years' follow-up, 13 (16%) mutation carriers developed HCM. Cox regression analysis showed age (hazard ratio (HR) 1.08, p = 0.01), pathological Q wave (HR 8.56; p = 0.01), and maximal wall thickness (HR 1.94; p = 0.01) to be independent predictors of the development of HCM. GLS was not predictive of the development of HCM (HR 0.78, p = 0.07).

conclusionGLS is increased in HCM mutation carriers without hypertrophic changes. GLS was of no clear prognostic value for the development of HCM during follow-up, in contrast to age, pathological Q waves and maximal wall thickness.

Indexed as

CardiomyopathyGeneticsHypertrophyLong-term follow-upScreening

Identifiers

PMID30680638
PMCPMC6393574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.